interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Risdiplam

Generic competition · all medicines · read 12 November 2026

Is there a generic of Risdiplam, and who makes it?

Risdiplam appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Risdiplam2 dosage-form groups in the Orange Book
0generic makers listed
  1. Risdiplam appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

For Solution, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Evrysdi. No generic is listed as marketed.

20202025203020352040204501brand 2020data datePatent 9586955 listed to expire 8 February 2033Patent 9969754 listed to expire 11 May 2035Patent 11827646 listed to expire 25 January 2036Patent 11938136 listed to expire 8 November 2036Patent 12350273 listed to expire 1 October 2038Patent 11534444 listed to expire 4 October 2038Patent 12122789 listed to expire 15 April 2041Exclusivity ODE-334 to 7 August 2027Exclusivity ODE-400 to 27 May 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 7 August 2027Exclusivity ODE-334 Evrysdi
  • 27 May 2029Exclusivity ODE-400 Evrysdi
  • 8 February 2033Patent 9586955 drug substance
  • 11 May 2035Patent 9969754 drug substance
  • 25 January 2036Patent 11827646
  • 8 November 2036Patent 11938136 drug product
  • 1 October 2038Patent 12350273
  • 4 October 2038Patent 11534444
  • 15 April 2041Patent 12122789 drug substance

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Evrysdi. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 9586955 listed to expire 8 February 2033Patent 9969754 listed to expire 11 May 2035Patent 11827646 listed to expire 25 January 2036Patent 12350273 listed to expire 1 October 2038Patent 11534444 listed to expire 4 October 2038Patent 12122789 listed to expire 15 April 2041
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 8 February 2033Patent 9586955 drug substance
  • 11 May 2035Patent 9969754 drug substance
  • 25 January 2036Patent 11827646
  • 1 October 2038Patent 12350273
  • 4 October 2038Patent 11534444
  • 15 April 2041Patent 12122789 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.